Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
AssigneeApellis Pharmaceuticals, Inc.
InventorsCedric Francois, Pascal Deschatelets
Life of this patent
Estimating the term…
Loading patent…
AssigneeApellis Pharmaceuticals, Inc.
InventorsCedric Francois, Pascal Deschatelets
Estimating the term…
In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.
A physiologically acceptable or pharmaceutical grade composition comprising a cell-reactive compstatin analog.
-33. (canceled)
An isolated cell or organ having a compstatin analog covalently bonded thereto.
-53. (canceled)
A long-acting compstatin analog comprising a clearance reducing moiety (CRM) that has a molecular weight of at least 20 kilodaltons (kD).
-113. (canceled)
-136. (canceled)
Dependencies are inferred from the claim text.